Category: Opinion

In this opinion piece, Dr. Frank Borriello reflects on the devastating impact of recent U.S. federal funding cuts on scientific research. Drawing from his own experiences as a beneficiary of NIH investments, he highlights the economic and societal value of supporting science and warns of the long-te...

In this opinion piece, Alloplex CEO Dr. Frank Borriello reflects on a recent gene therapy discontinuation, arguing it reveals a critical misalignment in biotech. He calls for a strategic shift, urging the industry to prioritize patient-centric solutions over chasing trendy technologies.

CEO Frank Borriello discusses how recent FDA departures are reshaping regulatory risk and calls for industry vigilance in maintaining rigorous drug evaluation standards.

The following commentary by our CEO, Dr. Frank Borriello, is about the current challenges and limitations of immune checkpoint inhibitor (ICI) combinations in cancer treatment. Dr. Borriello touches on the need for a strategic shift in approach. This article – published in Endpoints – hi...

Opinion on the importance of first developing robust datasets for future AI efforts.

Alloplex CEO agrees, says machine learning and AI being conflated.

Dr. Borriello speaks of collective responsibility amongst all involved in developing drugs to combat cancer.

Dr. Borriello shares his thoughts on an opinion piece that appeared in the New York Times.

Alloplex CEO comments on Washington Post article and data that shows 'Big Pharma's high prices don't drive innovation'.